Immunomodulation of Multiple Myeloma Bone Disease

Clinical Reviews in Bone and Mineral Metabolism

Volumn 7, Issue 4, 2009, Pages 293-300

  Grano, Maria ^a   Brunetti, Giacomina ^a   Colucci, Silvia ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Multiple myeloma; Myeloma cells; Osteoclast; Osteolysis; T cells

Indexed keywords

CYTOKINE; DECOY RECEPTOR 3; GAMMA INTERFERON; INTERLEUKIN 3; INTERLEUKIN 7; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; BONE CELL; BONE DESTRUCTION; BONE DISEASE; CANCER CELL; CELL ACTIVATION; CELL SURVIVAL; CYTOKINE PRODUCTION; CYTOLOGY; DENDRITIC CELL; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MULTIPLE MYELOMA; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PLASMA CELL; PREVALENCE; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 70449521102     PISSN: 15348644     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12018-009-9058-2     Document Type: Review

References (105)

1. RE Coleman 1997 Skeletal complications of malignancy Cancer 80 1588 1594 9362426
2. D Billadeau G Ahmann P Greipp B Van Ness 1993 The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell J Exp Med 178 1023 1031 8350044
3. W Matsui CA Huff Q Wang MT Malehorn J Barber Y Tanhehco BD Smith CI Civin RJ Jones 2004 Characterization of clonogenic multiple myeloma cells Blood 103 2332 2336 14630803
4. Anderson KC, Shaughnessy JD Jr, Barlogie B, Harousseau JL, Roodman GD. Multiple myeloma. Hematology Am Soc Hematol Educ Program. 2002;214-40.
5. DL Lacey HL Tan J Lu S Kaufman G Van W Qiu A Rattan S Scully F Fletcher T Juan M Kelley TL Burgess WJ Boyle AJ Polverino 2000 Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo Am J Pathol 157 435 448 10934148
6. WS Simonet DL Lacey CR Dunstan M Kelley MS Chang R Luthy HQ Nguyen S Wooden L Bennett T Boone G Shimamoto M DeRose R Elliot A Colombero HL Tan G Trail J Sullivan E Davy N Bucay L Renshaw-Gegg TM Huges D Hill W Pattison P Campbell WJ Boyle 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 309 319 9108485
7. H Yasuda N Shima N Nakagawa SI Mochizuki K Yano N Fujise Y Sato M Goto K Yamaguchi M Kuriyama T Kanno A Murakami E Tsuda T Morinaga K Higashio 1998 Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro Endocrinology 139 1329 1337 9492069
8. DL Lacey E Timms HL Tan MJ Kelley CR Dunstan T Burgess R Elliott A Colombero G Elliott S Scully H Hsu J Sullivan N Hawkins E Davy C Capparelli A Eli YX Qian S Kaufman I Saros V Shalhoub G Senaldi J Guo J Delaney WJ Boyle 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 165 176 9568710
9. Y Choi KM Woo SH Ko YJ Lee SJ Park HM Kim BS Kwon 2001 Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells Eur J Immunol 31 2179 2188 11449372
10. S Colucci G Brunetti R Rizzi A Zonno G Mori G Colaianni D Del Prete R Faccio A Liso S Capalbo V Liso A Zallone M Grano 2004 T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction Blood 104 3722 3730 15308561
11. MN Weitzmann S Cenci L Rifas J Haug J Dipersio R Pacifici 2001 T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms J Bone Miner Res 16 328 337 11204433
12. N Giuliani S Colla R Sala M Moroni M Lazzaretti S La Monica S Bonomini M Hojden G Sammarelli S Barille R Bataille V Rizzoli 2002 Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease Blood 100 4615 4621 12393684
13. SL Teitelbaum 2004 Postmenopausal osteoporosis, T cells, and immune dysfunction Proc Natl Acad Sci USA 101 16711 16712 15557556
14. L Rifas S Arackal 2003 T cells regulate the expression of matrix metalloproteinase in human osteoblasts via a dual mitogen-activated protein kinase mechanism Arthritis Rheum 48 993 1001 12687541
15. KHG Mills JC Cawley 1983 Abnormal monoclonal antibody-defined helper/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage Br J Haematol 53 271 275 6217831
16. N Kay T Leong RA Kyle, et al. 1999 Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a study of the eastern cooperative oncology group (E9487) Leuk Lymph 33 127 133
17. LM Pilarski EJ Andrews HM Serra BA Ruether MJ Mant 1989 Comparative analysis of immunodeficiency in patients with monoclonal gammopathy of undetermined significance and patients with untreated multiple myeloma Scand J Immunol 29 217 228 2784225
18. A Carter I Silvian I Tatarsky G Spira 1986 Impaired immunoglobulin synthesis in multiple myeloma: a B-cell dysfunction Am J Hematol 22 143 154 2939711
19. H Mellstedt G Holm D Pettersson M Björkholm B Johansson C Lindemalm D Peest A Ahre 1982 T cells in monoclonal gammopathies Scand J Haematol 29 57 64 6214842
20. A Tienhaara TT Pelliniemi 1994 Peripheral blood lymphocyte subsets in multiple myeloma and monoclonal gammopathy of undetermined significance Clin Lab Haematol 16 213 223 7828409
21. DE Joshua RD Brown PJ Ho J Gibson 2008 Regulatory T cells and multiple myeloma Clin Lymphoma Myeloma 8 283 286 18854282
22. RH Prabhala P Neri JE Bae P Tassone MA Shammas CK Allam JF Daley D Chauhan E Blanchard HS Thatte KC Anderson NC Munshi 2006 Dysfunctional T regulatory cells in multiple myeloma Blood 107 301 304 16150935
23. M Beyer M Kochanek T Giese E Endl MR Weihrauch PA Knolle S Classen JL Schultze 2006 In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma Blood 107 3940 3949 16410445
24. S Feyler M von Lilienfeld-Toal S Jarmin L Marles A Rawstron AJ Ashcroft RG Owen PJ Selby G Cook 2009 CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-) alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden Br J Haematol 144 686 695 19133978
25. R Garcia-Sanz M Gonzalez A Orfao, et al. 1996 Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications Br J Haematol 93 81 88 8611480
26. A Osterborg B Nilsson M Bjorkholm G Holm H Mellstedt 1990 Natural killer cell activity in monoclonal gammopathies: relation to disease activity Eur J Haematol 45 153 157 1699786
27. MA King MA Radicchi-Mastrioanni 1996 Natural killer cells and CD56+ T cells in the blood of multiple myeloma patients: analysis by 4-colour flow cytometry Cytometry 26 121 124 8817087
28. M Perez-Andres J Almeida M Martin-Ayuso MJ Moro MA Garcia-Marcos I Moreno M Dominguez J Galende N Heras MI Gonzalez JF San Miguel A Orfao 2004 Red Espanola de Mieloma Multiple. interaction between clonal plasma cells and the immune system in plasma cell dyscrasias J Biol Regul Homeost Agents 18 161 165 15471221
29. KM Dhodapkar S Barbuto P Matthews A Kukreja A Mazumder D Vesole S Jagannath MV Dhodapkar 2008 Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma Blood 112 2878 2885 18669891
30. M Pérez-Andres J Almeida M Martin-Ayuso MJ Moro G Martin-Nuñez J Galende J Hernandez G Mateo JF San Miguel A Orfao Spanish Network on Multiple Myeloma Spanish Network of Cancer Research Centers 2006 Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire Cancer 106 1296 1305 16475149
31. D Grcevic SK Lee A Marusic JA Lorenzo 2000 Depletion of CD4 and CD8 T lymphocytes in mice in vivo enhances 1, 25-dihydroxyvitamin D3-stimulated osteoclast-like cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis J Immunol 165 4231 4238 11035056
32. NJ Horwood V Kartsogiannis JM Quinn E Romas TJ Martin MT Gillespie 1999 Activated T lymphocytes support osteoclast formation in vitro Biochem Biophys Res Commun 265 144 150 10548505
33. YY Kong U Feige I Sarosi B Bolon A Tafuri S Morony C Capparelli J Li R Elliott S McCabe T Wong G Campagnuolo E Moran ER Bogoch G Van LT Nguyen PS Ohashi DL Lacey E Fish WJ Boyle JM Penninger 1999 Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand Nature 402 304 309 10580503
34. Teng YT, Nguyen H, Gao X, Kong YY, Gorczynski RM, Singh B, Ellen RP, Penninger JM. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest. 2000;106:R59-7.
35. H Takayanagi K Ogasawara S Hida T Chiba S Murata K Sato A Takaoka T Yokochi H Oda K Tanaka K Nakamura T Taniguchi 2000 T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma Nature 408 600 605 11117749
36. P D'Amelio A Grimaldi GP Pescarmona C Tamone I Roato G Isaia 2005 Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis FASEB J 19 410 412 15611151
37. I Roato M Grano G Brunetti S Colucci A Mussa O Bertetto R Ferracini 2005 Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement FASEB J 19 228 230 15550550
38. BR Wong J Rho J Arron E Robinson J Orlinick M Chao S Kalachikov E Cayani FS Bartlett III WN Frankel SY Lee Y Choi 1997 TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells J Biol Chem 272 25190 25194 9312132
39. N Kim M Takami J Rho R Josien Y Choi 2002 A novel member of the leukocyte receptor complex regulates osteoclast differentiation J Exp Med 195 201 209 11805147
40. YY Kong H Yoshida I Sarosi HL Tan E Timms C Capparelli S Morony AJ Oliveira-dos-Santos G Van A Itie W Khoo A Wakeham CR Dunstan DL Lacey TW Mak WJ Boyle JM Penninger 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature 397 315 323 9950424
41. MA Lomaga WC Yeh I Sarosi GS Duncan C Furlonger A Ho S Morony C Capparelli G Van S Kaufman A van der Heiden A Itie A Wakeham W Khoo T Sasaki Z Cao JM Penninger CJ Paige DL Lacey CR Dunstan WJ Boyle DV Goeddel TW Mak 1999 TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling Genes Dev 13 1015 1024 10215628
42. H Takayanagi S Kim T Taniguchi 2002 Signaling crosstalk between RANKL and interferons in osteoclast differentiation Arthritis Res 4 S227 S232 12110142
43. K Nosaka T Miyamoto T Sakai H Mitsuya T Suda M Matsuoka 2002 Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells Blood 99 634 640 11781248
44. N Giuliani R Bataille C Mancini M Lazzaretti S Barille 2001 Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment Blood 98 3527 3533 11739153
45. RN Pearse EM Sordillo S Yaccoby BR Wong DF Liau N Colman J Michaeli J Epstein Y Choi 2001 Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression Proc Natl Acad Sci USA 98 11581 11586 11562486
46. YW Qiang Y Chen O Stephens N Brown B Chen J Epstein B Barlogie JD Shaughnessy Jr 2008 Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma Blood 112 196 207 18305214
47. T Standal C Seidel O Hjertner T Plesner RD Sanderson A Waage M Borset A Sundan 2002 Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells Blood 100 3002 3007 12351414
48. U Heider C Langelotz C Jakob I Zavrski C Fleissner J Eucker K Possinger LC Hofbauer O Sezer 2003 Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma Clin Cancer Res 9 1436 1440 12684416
49. O Sezer U Heider C Jakob J Eucker K Possinger 2002 Human bone marrow myeloma cells express RANKL J Clin Oncol 20 353 354 11773196
50. O Sezer U Heider C Jakob I Zavrski J Eucker K Possinger C Sers V Krenn 2002 Immunocytochemistry reveals RANKL expression of myeloma cells Blood 99 4646 4647 12066787
51. PI Croucher CM Shipman J Lippitt M Perry K Asosingh A Hijzen AC Brabbs EJ van Beek I Holen TM Skerry CR Dunstan GR Russell B Van Camp K Vanderkerken 2001 Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma Blood 98 3534 3540 11739154
52. S Roux V Meignin J Quillard S Roux V Meignin J Quillard G Meduri A Guiochon-Mantel JP Fermand E Milgrom X Mariette 2002 RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma Br J Haematol 117 86 92 11918537
53. V Krishnan HU Bryant OA Macdougald 2006 Regulation of bone mass by Wnt signaling J Clin Invest 116 1202 1209 16670761
54. E Tian F Zhan R Walker E Rasmussen Y Ma B Barlogie D Shaughnessy 2003 The role of the wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma N Engl J Med 349 2483 2494 14695408
55. MC Politou DJ Heath A Rahemtulla R Szydlo A Anagnostopoulos MA Dimopoulos, et al. 2006 Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation Int J Cancer 119 1728 1731 16646053
56. M Kaiser M Mieth P Liebisch R Oberlander J Rademacher C Jakob L Kleeberg C Fleissner E Braendle M Peters D Stover O Sezer U Heider 2008 Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma Eur J Haematol 80 490 494 18331598
57. S Yaccoby W Ling F Zhan R Walker B Barlogie JD Shaughnessy Jr 2007 Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo Blood 109 2106 2111 17068150
58. DJ Heath AD Chantry CH Buckle L Coulton JD Shaughnessy Jr HR Evans JA Snowden DR Stover K Vanderkerken PI Croucher 2009 Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma J Bone Miner Res 24 425 436 19016584
59. SA Marsters RA Pitti JP Sheridan A Ashkenazi 1999 Control of apoptosis signaling by Apo2 ligand Recent Progr Horm Res 54 225 234 10548878
60. G Zauli P Secchiero 2006 The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology Cytokine Growth Factor Rev 17 245 257 16750931
61. JG Emery P McDonnell MB Burke KC Deen S Lyn C Silverman E Dul ER Appelbaum C Eichman R DiPrinzio RA Dodds IE James M Rosenberg JC Lee PR Young 1998 Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL J Biol Chem 273 14363 14367 9603945
62. I Holen PI Croucher FC Hamdy CL Eaton 2002 Osteoprotegerin is a survival factor for human prostate cancer cell Cancer Res 62 1619 1623 11912131
63. CM Shipman PI Croucher 2003 Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells Cancer Res 63 912 916 12615702
64. RM Pitti SA Marsters DA Lawrence M Roy FC Kischkel P Dowd A Huang CJ Donahue SW Sherwood DT Baldwin PJ Godowski WI Wood AL Gurney KJ Hillan RL Cohen AD Goddard D Botstein A Ashkenazi 1998 Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer Nature 396 699 703 9872321
65. W Roth S Isenmann M Nakamura M Platten W Wick P Kleihues M Bähr H Ohgaki A Ashkenazi M Weller 2001 Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis Cancer Res 61 2759 2765 11289159
66. C Bai B Connolly ML Metzker CA Hilliard X Liu V Sandig A Soderman SM Galloway Q Liu CP Austin CT Caskey 2000 Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster Proc Natl Acad Sci USA 97 1230 1235 10655513
67. CR Yang JH Wang SL Hsieh SM Wang TL Hsu WW Lin 2004 Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells Cell Death Differ 11 Suppl 1 S97 S107 15002040
68. CH Tang TL Hsu WW Lin MZ Lai RS Yang SL Hsieh WM Fu 2007 Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice J Biol Chem 282 2346 2354 17099218
69. Colucci S, Brunetti G, Mori G, Oranger A, Centonze M, Mori C, Cantatore FP, Tamma R, R Rizzi, Liso V, Zallone A, Grano M. Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients. Leukemia. 2009 [Epub ahead of print].
70. HI Sati M Greaves JF Apperley RG Russell PI Croucher 1999 Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma Br J Haematol 104 350 357 10050719
71. F Silvestris P Cafforio N Calvani F Dammacco 2004 Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells Br J Haematol 126 475 486 15287939
72. N Abildgaard H Glerup J Rungby K Bendix-Hansen M Kassem, et al. 2000 Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma Eur J Haematol 64 121 129 10997332
73. MS Nanes 2003 Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology Gene 321 1 15 14636987
74. H Kitaura MS Sands K Aya P Zhou T Hirayama B Uthgenannt S Wei S Takeshita DV Novack MJ Silva Y Abu-Amer FP Ross SL Teitelbaum 2004 Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo J Immunol 173 4838 4846 15470024
75. H Takayanagi K Ogasawara S Hida T Chiba S Murata K Sato T Akinori T Yokochi H Oda K Tanaka K Nakamura T Taniguchi 2000 T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma Nature 408 600 605 11117749
76. GS Firestein NJ Zvaifler 1990 How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum 33 768 773 2194461
77. RW Kinne E Palombo-Kinne F Emmrich 1997 T-cells in the pathogenesis of rheumatoid arthritis villains or accomplices? Biochim Biophys Acta 1360 109 141 9128178
78. MN Weitzmann S Cenci L Rifas C Brown R Pacifici 2000 Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines Blood 96 1873 1878 10961889
79. G Toraldo C Roggia WP Qian R Pacifici MN Weitzmann 2003 IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells Proc Natl Acad Sci USA 100 125 130 12490655
80. M Iwata L Graf N Awaya B Torok-Storb 2002 Functional interleukin-7 receptors (IL-7Rs) are expressed by marrow stromal cells: binding of IL-7 increases levels of IL-6 mRNA and secreted protein Blood 100 1318 1325 12149213
81. N Giuliani S Colla F Morandi M Lazzaretti R Sala S Bonomini M Grano S Colucci M Svaldi V Rizzoli 2005 Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation Blood 106 2472 2483 15933061
82. F Merico L Bergui MG Gregoretti P Ghia G Aimo IJ Lindley F Caligaris-Cappio 1993 Cytokines involved in the progression of multiple myeloma Clin Exp Immunol 92 27 31 8467562
83. N Giuliani F Morandi S Tagliaferri S Colla S Bonomini G Sammarelli V Rizzoli 2006 Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients Blood 107 841 842 16401825
84. JW Lee HY Chung LA Ehrlich DF Jelinek NS Callander GD Roodman SJ Choi 2004 IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells Blood 103 2308 2315 14615378
85. BE Barton R Mayer 1989 IL-3 induces differentiation of bone marrow precursor cells to osteoclast-like cells J Immunol 143 3211 3216 2809196
86. LA Ehrlich HY Chung I Ghobrial SJ Choi F Morandi S Colla V Rizzoli GD Roodman N Giuliani 2005 IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma Blood 106 1407 1414 15878977
87. J Banchereau F Briere C Caux J Davoust S Lebecque YJ Liu B Pulendran K Palucka 2000 Immunobiology of dendritic cells Annu Rev Immunol 18 767 811 10837075
88. GJ Randolph K Inaba DF Robbiani RM Steinman WA Muller 1999 Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo Immunity 11 753 761 10626897
89. GJ Randolph G Sanchez-Schmitz RM Liebman K Schakel 2002 The CD16(+) (FcgammaRIII(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting J Exp Med 196 517 527 12186843
90. T Miyamoto O Ohneda F Arai K Iwamoto S Okada K Takagi DM Anderson T Suda 2001 Bifurcation of osteoclasts and dendritic cells from common progenitors Blood 98 2544 2554 11588053
91. A Rivollier M Mazzorana J Tebib M Piperno T Aitsiselmi C Rabourdin-Combe P Jurdic C Servet-Delprat 2004 Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment Blood 104 4029 4037 15308576
92. T Hashimoto M Abe Y Tanaka E Sekimoto T Oshima 2005 Macrophage inflammatory protein-1 may cause reciprocal regulation of osteoclast and dendritic cell differentiation from monocytes in myeloma (abstract) Haematologica J 90 46
93. SD Wolpe G Davatelis B Sherry B Beutler DG Hesse HT Nguyen LL Moldawer CF Nathan SF Lowry A Cerami 1988 Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties J Exp Med 167 570 581 3279154
94. T Kukita H Nomiyama Y Ohmoto A Kukita T Shuto T Hotokebuchi Y Sugioka R Miura T Iijima 1997 Macrophage inflammatory protein-1 alpha (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment Lab Invest 76 399 406 9121122
95. BA Scheven JS Milne I Hunter SP Robins 1999 Macrophage-inflammatory protein-1alpha regulates preosteoclast differentiation in vitro Biochem Biophys Res Commun 254 773 778 9920817
96. JH Han SJ Choi N Kurihara M Koide Y Oba GD Roodman 2001 Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand Blood 97 3349 3353 11369623
97. M Abe K Hiura J Wilde K Moriyama T Hashimoto S Ozaki S Wakatsuki M Kosaka S Kido D Inoue T Matsumoto 2002 Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma Blood 100 2195 2202 12200385
98. SJ Choi JC Cruz F Craig H Chung RD Devlin GD Roodman M Alsina 2000 Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma Blood 96 671 675 10887133
99. GD Roodman 1997 Mechanisms of bone lesions in multiple myeloma and lymphoma Cancer 80 1557 1563 9362422
100. S Uneda H Hata F Matsuno N Harada Y Mitsuya F Kawano H Mitsuya 2003 Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM Br J Haematol 120 53 55 12492576
101. E Terpos M Politou R Szydlo JM Goldman JF Apperley A Rahemtulla 2003 Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma Br J Haematol 123 106 109 14510950
102. F Magrangeas V Nasser H Avet-Loiseau B Loriod O Decaux S Granjeaud F Bertucci D Birnbaum C Nguyen JL Harousseau R Bataille R Houlgatte S Minvielle 2003 Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease Blood 101 4998 5006 12623842
103. T Hashimoto M Abe T Oshima H Shibata S Ozaki D Inoue T Matsumoto 2004 Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma Br J Haematol 125 38 41 15015966
104. SJ Choi Y Oba Y Gazitt M Alsina J Cruz J Anderson GD Roodman 2001 Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease J Clin Invest 108 1833 1841 11748267
105. BO Oyajobi G Franchin PJ Williams D Pulkrabek A Gupta S Munoz B Grubbs M Zhao D Chen B Sherry GR Mundy 2003 Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease Blood 102 311 319 12649140